Poor GMP/GDP Practice found in US Warehouse
Recommendation

8 September 2026
Basel, Switzerland
Specifics in the Distribution of Medicinal Products
Any contract giver is ultimately responsible for the product in the marketplace even where certain activities are contracted out. They are therefore responsible for defining appropriate controls in a clear written contract and monitor to ensure that the contract acceptor performs the outsourced activity as required. Audits should be undertaken at a frequency determined by the contract giver's risk assessment. If periodic audits of the contract acceptor are not frequent enough there is a risk that GMP and GDP standards slip without the contract giver being aware until a significant issue occurs.
What can go wrong for example in a warehouse was now published in a news release by the U.S. Food and Drug Administration FDA. In a warehouse in Arkansas, USA, which also stores and distributes over-the-counter (OTC) drugs obtained through brokers, observations were made beyond belief. The investigators found "alarming" insanitary conditions including "multiple live and dead rodents, rodent nesting, live raccoons, live cats, a dead possum, animal feces, and urine-stained products in and around the company's seven warehouses".
As a result, FDA issued two Administrative Detention Orders calling for the detention of all human and animal food products and drugs.
Source: FDA News Release "FDA seizes food and medical products held under insanitary conditions at an Arkansas grocery warehouse".
Related GMP News
14.07.2026USP Proposes to Revise the Definition of Controlled Room Temperature in Chapter <659>
14.07.2026GDP in Hong Kong: Authority Provides Additional Information
14.07.2026GDP Inspection Responses: MHRA’s Expectations for AI Use in GxP Replies
14.07.2026FDA Warning Letter to Amazon: Unapproved New Drugs Sold via Online Marketplace
18.06.2026GDPA Participated as an Observer in the EMA GMDP-IWG Interested Parties Meeting


